Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of hospital-acquired infections.
• Effective antimicrobial therapy is crucial for managing MRSA infections and improving patient outcomes.

Purpose of the Study:

• To evaluate the clinical outcomes, including survival and organ toxicity, associated with different anti-MRSA antimicrobials.
• To compare the efficacy and safety of vancomycin, linezolid, teicoplanin, and daptomycin in treating MRSA infections.

Main Methods:

• Prospective database review of 247 patients with confirmed MRSA infections across 7 Japanese hospitals (April 2014 - March 2015).
• Analysis of 30-day mortality, organ toxicity (specifically renal dysfunction), and initial antimicrobial treatment.
• Calculation of Hazard Ratios (HR) and 95% Confidence Intervals (CIs) to assess treatment associations.

Main Results:

• Overall 30-day mortality was 12%. Common infection sites included lungs (41%), skin/soft tissue (30%), and bones/joints (9%). Bacteremia occurred in 28% of patients.
• Vancomycin, used in 71% of patients, was associated with lower survival (HR=2.47) and higher mortality in lung infections (HR=4.85) compared to other agents.
• Higher incidence of renal dysfunction was observed with vancomycin trough serum concentrations >15 mg/dL.

Conclusions:

• In real-world settings, vancomycin demonstrated a trend towards higher 30-day mortality and increased renal dysfunction compared to other anti-MRSA agents.
• The observed differences among antimicrobials other than vancomycin require further investigation to determine their clinical significance.